LENZ Therapeutics Inc is a pioneering biopharmaceutical company focused on developing innovative therapies for neurological disorders, with an emphasis on addressing significant unmet needs in the central nervous system (CNS). Leveraging advanced drug formulation and delivery technologies, the company boasts a robust pipeline of proprietary assets designed to improve patient outcomes. With strategic partnerships and a strong commitment to rigorous clinical research, LENZ is well-positioned for substantial growth and aims to establish itself as a key player in the biopharmaceutical sector, capitalizing on emerging opportunities within the evolving healthcare market.
| Revenue (TTM) | $20.99M |
| Gross Profit (TTM) | $19.50M |
| EBITDA | $-117.98M |
| Operating Margin | -2322.00% |
| Return on Equity | -49.70% |
| Return on Assets | -31.20% |
| Revenue/Share (TTM) | $0.70 |
| Book Value | $7.86 |
| Price-to-Book | 0.75 |
| Price-to-Sales (TTM) | 9.16 |
| EV/Revenue | 2.645 |
| EV/EBITDA | -7.99 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $31.35M |
| Float | $18.48M |
| % Insiders | 2.65% |
| % Institutions | 109.98% |
Volatility is currently expanding
VIZZ is now available for those who qualify through a convenient telehealth platform in addition to existing access through eye care professionals
SAN DIEGO and MELBOURNE, Australia, June 24, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Arrotex Pharmaceuticals Pty Ltd. (“Arrotex”) today announced an exclusive license and commercialization agreement for Arrotex to register and commercialize VIZZ™ for the treatment of presbyopia in Australia and New Zealand.
LENZ Therapeutics, Inc. (NASDAQ:LENZ) said Everest Medicines has acquired the rights to develop and commercialize VIZZ, also known as LNZ100, in Greater China. Under the agreement, Everest Medicines (HKEX:1952) takes on development and commercialization of the drug in the Greater China market, LENZ said.
SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences:
LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call Transcript
LENZ Therapeutics NASDAQ: LENZ reported first-quarter 2026 results that showed continued prescription growth for its presbyopia eye drop VIZZ, while management acknowledged that new patient adoption and routine prescribing by eye care professionals are developing more gradually than expected.
Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ® product sales Approximately 46,000 paid prescriptions filled and over 10,000 prescribing eye care professionals from launch through Q1 2026 Together with Sarah Jessica Parker, launched the DTC campaign in Q1 2026 Expanded sales force on-track to be fully deployed by the end of Q2 2026 Management to host conference call today, May 11, 2026, at 4:30 p.m. EDT SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today reported financial results for the first quarter ended March 31, 2026 and recent corporate highlights.
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Monday, May 11, 2026, at 4:30 p.m. EDT to report its first quarter 2026 financial results and recent corporate highlights.
MHRA submission follows EMA validation of the VIZZ MAA in March 2026 Sixth ex-U.S. regulatory submission for VIZZ underscores accelerating global expansion SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) today announced that it has submitted a Marketing Authorization Application (MAA) to the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for the review and approval of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia in adults. Since receiving U.S. Food and Drug Administration (FDA) approval in July 2025, LENZ has moved rapidly to expand global access to VIZZ, with submission of the MAA in the United Kingdom representing the sixth ex-U.S. regulatory submission for VIZZ.
